BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Förster D, Reiser G. Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies. Purinergic Signal 2015;11:441-54. [PMID: 26407872 DOI: 10.1007/s11302-015-9471-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Andrejew R, Glaser T, Oliveira-Giacomelli Á, Ribeiro D, Godoy M, Granato A, Ulrich H. Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. Adv Exp Med Biol 2019;1201:275-353. [PMID: 31898792 DOI: 10.1007/978-3-030-31206-0_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal MT, Novak I, Schöneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Müller CE. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 2020;177:2413-33. [PMID: 32037507 DOI: 10.1111/bph.15005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 26.0] [Reference Citation Analysis]
3 Bladowski M, Gawrys J, Gajecki D, Szahidewicz-Krupska E, Sawicz-Bladowska A, Doroszko A. Role of the Platelets and Nitric Oxide Biotransformation in Ischemic Stroke: A Translative Review from Bench to Bedside. Oxid Med Cell Longev 2020;2020:2979260. [PMID: 32908630 DOI: 10.1155/2020/2979260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Oliveira-Giacomelli Á, Naaldijk Y, Sardá-Arroyo L, Gonçalves MCB, Corrêa-Velloso J, Pillat MM, de Souza HDN, Ulrich H. Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. Front Pharmacol 2018;9:325. [PMID: 29692728 DOI: 10.3389/fphar.2018.00325] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
5 Czarnecka J, Porowińska D, Bajek A, Hołysz M, Roszek K. Neurogenic Differentiation of Mesenchymal Stem Cells Induces Alterations in Extracellular Nucleotides Metabolism. J Cell Biochem 2017;118:478-86. [PMID: 27472650 DOI: 10.1002/jcb.25664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Burnstock G. Purinergic Signalling: Therapeutic Developments. Front Pharmacol 2017;8:661. [PMID: 28993732 DOI: 10.3389/fphar.2017.00661] [Cited by in Crossref: 170] [Cited by in F6Publishing: 164] [Article Influence: 34.0] [Reference Citation Analysis]
7 Zarrinmayeh H, Territo PR. Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications. Mol Imaging 2020;19:1536012120927609. [PMID: 32539522 DOI: 10.1177/1536012120927609] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
8 Xue B, Xie Y, Xue Y, Hu N, Zhang G, Guan H, Ji M. Involvement of P2X7 receptors in retinal ganglion cell apoptosis induced by activated Müller cells. Exp Eye Res 2016;153:42-50. [PMID: 27720859 DOI: 10.1016/j.exer.2016.10.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
9 Kitamura K, Ito R, Umehara K, Morio H, Saito K, Suzuki S, Hashimoto M, Saito Y, Anzai N, Akita H, Chiba K, Furihata T. Differentiated HASTR/ci35 cells: A promising in vitro human astrocyte model for facilitating CNS drug development studies. J Pharmacol Sci 2018;137:350-8. [PMID: 30150146 DOI: 10.1016/j.jphs.2018.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Segal-Gavish H, Danino O, Barhum Y, Ben-Zur T, Shai E, Varon D, Offen D, Fischer B. A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice. J Alzheimers Dis 2017;58:389-400. [PMID: 28453480 DOI: 10.3233/JAD-161236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Alves M, Gomez-Villafuertes R, Delanty N, Farrell MA, O'Brien DF, Miras-Portugal MT, Hernandez MD, Henshall DC, Engel T. Expression and function of the metabotropic purinergic P2Y receptor family in experimental seizure models and patients with drug-refractory epilepsy. Epilepsia 2017;58:1603-14. [PMID: 28733972 DOI: 10.1111/epi.13850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
12 Engel T, Smith J, Alves M. Targeting Neuroinflammation via Purinergic P2 Receptors for Disease Modification in Drug-Refractory Epilepsy. J Inflamm Res 2021;14:3367-92. [PMID: 34305404 DOI: 10.2147/JIR.S287740] [Reference Citation Analysis]
13 Alves VS, Leite-Aguiar R, Silva JPD, Coutinho-Silva R, Savio LEB. Purinergic signaling in infectious diseases of the central nervous system. Brain Behav Immun 2020;89:480-90. [PMID: 32717399 DOI: 10.1016/j.bbi.2020.07.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
14 Barinov EF, Statinova EA, Sokhina VS, Faber TI. [Risks of progression of cerebrovascular pathology associated with the activity of the brain purinergic system]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:118-24. [PMID: 33244967 DOI: 10.17116/jnevro2020120101118] [Reference Citation Analysis]
15 Alves M, Beamer E, Engel T. The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy. Front Pharmacol 2018;9:193. [PMID: 29563872 DOI: 10.3389/fphar.2018.00193] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]